Pharmacyclics scores 'breakthrough' blood cancer drug approval

Pharmacyclics Inc. won Food and Drug Administration approval Wednesday for its blood cancer drug. Imbruvica, approved for patients previously treated with other drugs for mantle cell lymphoma, is the second drug from a Bay Area company to be green-lighted by the FDA under the agency's Breakthrough Therapy program...